The recent FDA approval of Aphexda combined with filgrastim improved the collection of stem cells in patients with multiple myeloma. Stem cell transplantation is an important treatment method for ...
(BPT) – Article is sponsored and developed by BioLineRx USA, Inc. Receiving a cancer diagnosis is overwhelming. There is a lot to learn while navigating numerous emotions. It’s always important to ...
Stem cell mobilization and transplantation represent pivotal advances in the management of multiple myeloma. This therapeutic approach involves stimulating the release of haematopoietic stem cells ...
An expert sat down with CURE® and discussed how stem cells are collected before a patient with myeloma undergoes a stem cell transplant. A stem cell transplant is one of the most efficient tools to ...
Dec 24, 2003 — Double transplantation of autologous stem cells improves overall survival among patients with myeloma, as compared to single transplant, according to results of a randomized trial ...
The FDA has approved the CXCR4 antagonist motixafortide (Aphexda) for use with filgrastim (Neupogen) to mobilize stem cells for autologous transplantation in multiple myeloma, BioLineRx announced on ...
Credit: BioLineRx. Aphexda is expected to be available in September 2023. The Food and Drug Administration (FDA) has approved Aphexda ™ (motixafortide) in combination with filgrastim (granulocyte ...
A bone marrow transplant is a medical process in which faulty or damaged stem cells are replaced with healthy ones. Our bone ...
1d
New Burixafor Clinical Data to be Presented as an Oral Presentation at the 2025 ASH Annual Meeting
REDWOOD CITY, Calif., Nov. 03, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: XCUR), a clinical-stage biotechnology company developing therapeutics for hematologic diseases, today announced that results from its ...
Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window A real-world analysis presented at the American Society of ...
Black survivors of multiple myeloma say the latest developments in treatment give them hope even as federal research cuts ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback